The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery

Genetic Vaccines and Therapy

Volumn 2, Issue , 2004, Pages

  Anson, Donald S ^a,b,c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ANTIRETROVIRUS AGENT; DOUBLE STRANDED RNA; GENOMIC RNA; RETROVIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; HOST CELL; HUMAN; IN VIVO STUDY; LENTIVIRINAE; METABOLIC DISORDER; NONHUMAN; ONCOGENE; REVIEW; RNA GENE; T CELL LEUKEMIA; VIRAL GENE DELIVERY SYSTEM; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 13844276394     PISSN: 14790556     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-0556-2-9     Document Type: Review

References (97)

1. Rosenburg N, Jolicoeur P: Retroviral pathogenesis. In Retroviruses Edited by: Coffin JM, Hughes SH, Varmus HE. Cold Spring Harbor Laboratory Press; 1997:475-586.
2. Nowinski RC, Hays EF: Oncogenicity of AKR endogenous leukemia viruses. J Virol 1978, 27:13-18.
3. Cloyd MW, Hartley JW, Rowe WP: Lymphomagenicity of recombinant mink cell focus-inducing murine leukemia viruses. J Exp Med 1980, 151:542-552.
4. Rowe WP, Cloyd MW, Hartley JW: Status of the association of mink cell focus-forming viruses with leukemogenesis. Cold Spring Harbor Symp Quant Biol 1980, 44:1265-1268.
5. Lenz J, Crowther R, Klimenko S, Haseltine W: Molecular cloning of a highly leukemogenic, ecotropic retrovirus from an AKR mouse. J Virol 1982, 43:943-951.
6. Meiering CD, Linial ML: Historical perspective of foamy virus epidemiology and infection. Clin Micro Rev 2001, 14: 65-176.
7. Diop OM, Gueye A, Dias-Tavares M, Kornfeld C, Faye A, Ave P, Huerre M, Corbet S, Barre-Sinoussi F, Müller-Trutwin MC: High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol 2000, 74:7538-7547.
8. Boeke JD, Stoye JP: Retrotransposons, endogenous retroviruses and the evolution of retroelements. In Retroviruses Edited by: Coffin JM, Hughes SH, Varmus HE. Cold Spring Harbor Laboratory Press; 1997:343-436.
9. Frank EK, Yuan HEH, Luban J: Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372: 59-362.
10. von Schwedler UK, Stuchell M, Muller B, Ward DM, Chung HY, Morita E, Wang HE, Davis T, He GP, Cimbora DM, Scott A, Krausslich HG, Kaplan J, Morham SG, Sundquist WI: The protein network of HIV budding. Cell 2003, 114:701-713.
11. Miller AD: Development and applications of retroviral vectors. In Retroviruses Edited by: Coffin JM, Hughes SH, Varmus HE. Cold Spring Harbor Laboratory Press; 1997:437-474.
12. McTaggart S, Al-Rubeai M: Retroviral vectors for human gene delivery. Biotechnol Adv 2002, 20:1-31.
13. Yu S-F, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF, Gilboa E: Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci (USA) 1986, 83:3194-3198.
14. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998, 72:9873-9880.
15. Otto E, Jones-Trower A, Vanin EF, Stambaugh K, Mueller SN, Anderson WF, McGarrity GJ: Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum Gene Ther 1994, 5:567-575.
16. Chong H, Starkey W, Vile RG: A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J Virol 1998, 72:2663-2670.
17. Shin S, Steffen DL: Frequent activation of the lck gene by promoter insertion and aberrant splicing in murine leukemia virus-induced rat lymphomas. Oncogene 1993, 8:141-149.
18. Robinson HL, Gagnon GC: Patterns of proviral insertion and deletion in avian leukosis virus-induced lymphomas. J Virol 1986, 57:28-36.
19. Selten G, Cuypers HT, Zijlstra M, Melief C, Berns A: Involvement of c-myc in MuMLV-induced T cell lymphomas in mice: Frequency and mechanisms of activation. EMBO J 1984, 3:3215-3222.
20. Lazo PA, Lee JS, Tsichlis PN: Long distance activation of the Myc protooncogene by provirus insertion in Mlvi1 or Mlvi4 in rat T-cell lymphomas. Proc Natl Acad Sci (USA) 1990, 87: 70-173.
21. Bartholomew CK, Ihle JN: Retroviral insertions 90 kilobases proximal to the Evi1 myeloid transforming gene activate transcription from the normal promoter. Mol Cell Biol 1991, 11:1820-1828.
22. Selten G, Cuypers HT, Berns A: Proviral activation of the putative oncogene Pim-1 in MuMLV induced T-cell lymphomas. EMBO J 1985, 4:1793-1798.
23. Lavu S, Reddy EP: Structural organization and nucleotide sequence of mouse c-myb oncogene: Activation in ABPL tumors is due to viral integration in an intron which results in the deletion of the 5′ coding sequences. Nucleic Acids Res 1986, 14:5309-5320.
24. DesGroseillers L, Villemur R, Jolicoeur P: The high leukemogenic potential of Gross passage A murine leukemia virus maps in the region of the genome corresponding to the long terminal repeat and to the 3′ end of env. J Virol 1983, 47:24-32.
25. DesGroseillers L, Rassart E, Jolicoeur P: Thymotropism of murine leukemia virus is conferred by its long terminal repeat. Proc Natl Acad Sci (USA) 1983, 80:4203-4207.
26. DesGroseillers L, Jolicoeur P: Mapping the viral sequences conferring leukemogenicity and disease specificity in Moloney and amphotropic murine leukemia viruses. J Virol 1984, 52: 48-456.
27. Lenz J, Celander D, Crowther RL, Patarca R, Perkins DW, Haseltine WA: Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 1984, 308:467-470.
28. Celander D, Haseltine WA: Tissue specific transcription preference as a determinant of cell tropism and leukaemogenic potential of murine retroviruses. Nature 1984, 312:159-162.
29. DesGroseillers L, Jolicoeur P: The tandem direct repeats within the long terminal repeat of murine leukemia viruses are the primary determinant of their leukemogenic potential. J Virol 1984, 52:945-952.
30. Ishimoto A, Takimoto M, Adachi A, Kakuyama M, Kato S, Kakimi K, Fukuoka K, Ogiu T, Matsuyama M: Sequences responsible for erythroid and lymphoid leukemia in the long terminal repeats of Friend-mink cell focus-forming and Moloney murine leukemia viruses. J Virol 1987, 61:1861-1866.
31. Yuen PH, Szurek PF: The reduced virulence of the thymotropic Moloney murine leukemia virus derivative MoMuLV-TB is mapped to 11 mutations within the U3 region of the long terminal repeat. J Virol 1989, 63:471-480.
32. Hallberg B, Schmidt J, Luz A, Pedersen FS, Grundström T: SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus. J Virol 1991, 65:4177-4181.
33. Tupper JC, Chen H, Hays EF, Bristol GC, Yoshimura FK: Contributions to transcriptional activity and to viral leukemogenicity made by sequences within and downstream of the MCF13 murine leukemia virus enhancer. J Virol 1992, 66:7080-7088.
34. Kabat D: Molecular biology of Friend viral erythroleukemia. Curr Top Microbiol Immunol 1989, 148:1-41.
35. Acha-Orbea H, MacDonald HR: Superantigens of mouse mammary tumor virus. Annu Rev Immunol 1995, 13:459-486.
36. Matsuoka M: Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003, 22:5131-5140.
37. Gardner MB, Henderson BE, Officer JE, Rongey RW, Parker JC, Oliver C, Estes JD, Huebner RJ: A spontaneous low motor neuron disease apparently caused by indigenous type-C RNA virus in wild mice. J Natl Cancer Inst 1973, 51:1243-1254.
38. Portis JL, Czub S, Robertson S, McAtee F, Chesebro B: Characterization of a neurological disease induced by a polytropic murine retrovirus. Evidence for differential targeting of ecotropic and polytropic viruses in the brain. J Virol 1995, 69: 070-8075.
39. Lynch WP, Sharpe AH: Differential glycosylation of the Cas-Br-E Env protein is associated with retrovirus-induced spongiform neurodegeneration. J Virol 2000, 74:1558-1565.
40. Jolicoeur P, Rassart E, DesGroseillers L, Robitaille Y, Paquette Y, Kay DG: Retrovirus-induced motor neuron disease of mice: Molecular basis of neurotropism and paralysis. Adv Neurol 1991, 56:481-493.
41. Johnson JM, Harrod R, Franchini G: Molecular biology and pathogenesis of the human T-cell leukemia/lymphotropic virus type-1 (HTLV-1). Int J Exp Pathol 2001, 82:135-147.
42. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P: The brain in AIDS: Central nervous system HIV-1 infection and AIDS dementia complex. Science 1988, 239:586-592.
43. Geleziunas R, Schipper HM, Wainberg MA: Pathogenesis and therapy of HIV-1 infection of the central nervous system. AIDS 1992, 6:1411-1426.
44. Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P, Costanzi G: Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr 1993, 6:42-45.
45. Albright AV, Soldan SS, Gonzalez-Scarano F: Pathogenesis of human immunodeficiency virus-induced neurological disease. J Neurovirol 2003, 9:222-227.
46. Mosier DE, Yetter RA, Morse HC: Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J Exp Med 1985, 161:766-784.
47. Mullins JI, Hoover EA, Overbaugh J, Quackenbush SL, Donahue PR, Poss ML: FeLV-FAIDS-induced immunodeficiency syndrome in cats. Vet Immunol Immunopathol 1989, 21:25-37.
48. Daniel MD, King NW, Letvin NL, Hunt RD, Sehgal PK, Desrosiers RC: A new type D retrovirus isolated from macaques with an immunodeficiency syndrome. Science 1984, 223:602-605.
49. Marx PA, Maul DH, Osborn KG, Lerche NW, Moody P, Lowenstine LJ, Henrickson RV, Arthur LO, Gilden RV, Gravell M, London WT, Sever JL, Levy JA, MInn RJ, Gardner MB: Simian AIDS: isolation of a type D retrovirus and transmission of the disease. Science 1984, 223:1083-1086.
50. Muralidhar G, Koch S, Haas M, Swain SL: CD4 T cells in murine acquired immunodeficiency syndrome: Polyclonal progression to anergy. J Exp Med 1992, 175:1589-1599.
51. Huang M, Jolicoeur P: Characterization of the gag fusion protein encoded by the defective Duplan retrovirus inducing murine acquired immunodeficiency syndrome. J Virol 1990, 64: 764-5772.
52. Pozsgay JM, Reid S, Pitha PM: Dissociation between lymphoproliferative responses and virus replication in mice with different sensitivities to retrovirus-induced immunodeficiency. J Virol 1993, 67:980-988.
53. Reinhart TA, Ghost AK, Hoover EA, Mullins JI: Distinct superinfection properties yet similar receptor utilization by cytopathic and noncytopathic feline leukemia viruses. J Virol 1993, 67: 153-5162.
54. Donahue PR, Quackenbush SL, Gallo MV, DeNoronha CMC, Overbaugh J, Hoover EA, Mullins JI: Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol 1991, 65:4461-4469.
55. Gardner MB, Luciw PA: Animal models of AIDS. FASEB J 1989, 3:2593-2606.
56. Stevenson M: HIV-1 pathogenesis. Nature Med 2003, 9:853-860.
57. Perk K: Characteristics of ovine and caprine lentivirus infections. Leukemia 1995, 9(suppl 1):S98-100.
58. Sellon DC: Equine infectious anemia. Vet Clin North Am Equine Pract 1993, 9:321-336.
59. Pepin M, Vitu C, Russo P, Mornex JF, Peterhans E: Maedi-visna virus infection in sheep: A review. Vet Res 1998, 29:341-367.
60. Mussman HC, Twiehaus MJ: Pathogenesis of reticuloendothelial virus disease in chicks- An acute runting syndrome. Avian Dis 1971, 15:483-502.
61. Hoover EA, Mullins JI: Feline leukemia virus infection and diseases. J Am Vet Med Assoc 1991, 199:1287-1297.
62. Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman S, Agricola B, Byrne E, Raffeld M, Moen R, Bacher J, Zsebo KM, Nienhuis AW: Helper virus induced T cell lymphoma in non-human primates after retroviral mediated gene transfer. J Exp Med 1992, 176:1125-1135.
63. Cosset F-L, Takeuchi Y, Battini J-L, Weiss RA, Collins MKL: High-titre packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995, 69:7430-7436.
64. Sheridan PL, Bodner M, Lynn A, Phuong TK, DePolo NJ, de la Vega DJ, O'Dea J, Nguyen K, McCormack JE, Driver DA, Townsend K, Ibanez CE, Sajjadi NC, Greengard JS, Moore MD, Respess J, Chang SMW, Dubensky TW, Jolly DJ, Sauter SL: Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: Improved safety and high titre. Mol Ther 2000, 2:262-275.
65. Iwakuma T, Cui Y, Chang L-J: Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999, 261: 20-132.
66. Rivière I, Brose K, Mulligan RC: Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci (USA) 1995, 92:6733-6737.
67. Pannell D, Ellis J: Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol 2001, 11:205-217.
68. Fuller M, Anson DS: Helper plasmids for production of HIV-1- derived vectors. Hum Gene Ther 2001, 12:2081-2093.
69. Herman SA, Coffin JM: Efficient packaging of readthrough RNA in ALV: Implications for oncogene transduction. Science 1987, 236:845-848.
70. Felder MP, Eychene A, Laugier D, Marx M, Dezelee P, Calothy G: Steps and mechanisms of oncogene transduction by retroviruses. Folia Biol (Praha) 1994, 40:225-235.
71. Li Z, Dullman J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert H-G, Fehse B, Baum C: Murine leukemia induced by retroviral marking. Science 2002, 296:497.
72. Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
73. Baum C, von Kalle C, Staal FJT, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA: Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004, 9:5-13.
74. Dave UP, Jenkins NA, Copeland NG: Gene therapy insertional mutagenesis insights. Science 2004, 303:333.
75. Hacein-Bey H, Cavazzana-Calvo M, Le Deist F, Dautry-Varsat A, Hivroz C, Riviere I, Danos O, Heard JM, Sugamura K, Fischer A, De Saint Basile G: γ-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 1996, 87:3108-3116.
76. Wahlers A, Schwieger M, Li Z, Meier-Tackmann D, Lindemann C, Eckert HG, von Laer D, Baum C: Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Ther 2001, 8:477-486.
77. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviere I, Blau CA, Richard RE, Sorrentino B, Nolta J, Malech H, Brenner M, Cornetta K, Cavagnaro J, High K, Glorioso J: American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003, 8: 80-187.
78. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, Candotti F: Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: Long-term results of the first clinical gene therapy trial. Blood 2003, 101: 563-2569.
79. Aiuti A, Ficara F, Cattaneo F, Bordignon C, Roncarolo MG: Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol 2003, 3:461-466.
80. Dong WF, Billia F, Atkins HL, Iscove NN, Minden MD: Expression of rhombotin 2 in normal and leukaemic haemopoietic cells. Br J Haematol 1996, 93:280-286.
81. Bode J, Benham C, Knopp A, Miekle C: Transcriptional augmentation: Modulation of gene expression by scaffold/matrix-attached regions (S/MAR elements). Crit Rev Eukaryot Gene Expr 2000, 10:73-90.
82. Wu X, Li Y, Crise B, Burgess SM: Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300:1749-1751.
83. Burgess-Beusse B, Farrell C, Gaszner M, Litt M, Mutskov V, Recillas-Targa F, Simpson M, West A, Felsenfeld G: The insulation of genes from external enhancers and silencing chromatin. Proc Natl Acad Sci (USA) 2002, 99:16433-16437.
84. Rameezani A, Hawley TS, Hawley RG: Performance- and safety-enhanced lentiviral vectors containing the human interferon-β scaffold attachment region and the chicken β-globin insulator. Blood 2003, 101:4717-4724.
85. Miyoshi H: Gene delivery to hematopoietic stem cells using lentiviral vectors. Methods Mol Biol 2004, 246:429-438.
86. Josephson NC, Trobridge G, Russell DW: Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors. Hum Gene Ther 2004, 15: 7-92.
87. Hawley RG, Covarrubias L, Hawley T, Mintz B: Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells. Proc Natl Acad Sci (USA) 1987, 84:2406-2410.
88. Yee J-K, Moores JC, Jolly DJ, Wolff JA, Respess JG, Friedmann T: Gene expression from transcriptionally disabled retroviral vectors. Proc Natl Acad Sci (USA) 1987, 84:5197-5201.
89. Olson P, Temin HM, Dornburg R: Unusually high frequency of reconstitution of long terminal repeats in U3-minus retrovirus vectors by DNA recombination or gene conversion. J Virol 1992, 66: 336-1343.
90. Flamant F, Aubert D, Legrand C, Cosset FL, Samarut J: Importance of 3′ non-coding sequences for efficient retrovirus-mediated gene transfer in avian cells revealed by self-inactivating vectors. J Gen Virol 1993, 74:39-46.
91. Olson P, Nelson S, Dornburg R: Improved self-inactivating retroviral vectors derived from spleen necrosis virus. J Virol 1994, 68:7060-7066.
92. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM: Development of a self-inactivating lentivirus vector. J Virol 1998, 72:8150-8157.
93. Anson DS, Fuller M: Rational development of a HIV-1 gene therapy vector. J Gene Med 2003, 5:829-838.
94. Ginn SL, Fleming J, Rowe PB, Alexander IE: Promoter interference mediated by the U3 region in early-generation HIV-1-derived lentivirus vectors can influence detection of transgene expression in a cell-type and species-specific manner. Hum Gene Ther 2003, 14:1127-1137.
95. Bai Y, Soda Y, Izawa K, Tanabe T, Kang X, Tojo A, Hoshino H, Miyoshi H, Asano S, Tani K: Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Ther 2003, 10:1446-1457.
96. Levasseur DN, Ryan TM, Pawlik KM, Townes TM: Correction of a mouse model of sickle cell disease: Lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 2003, 102:4312-4319.
97. Hanawa H, Hematti P, Keyvanfar K, Metzger ME, Krouse A, Donahue RE, Kepes S, Gray J, Dunbar CE, Persons DA, Nienhuis AW: Efficient Gene Transfer into Rhesus Repopulating Hematopoietic Stem Cells Using a Simian Immunodeficiency Virus-Based Lentiviral Vector System. Blood in press. 2004 Feb 19